Clinical indications for immune checkpoint inhibitor (ICI) therapy are rapidly expanding for various stages of several solid tumors. The success of ICIs results from a complex interplay between cancer cells and their immune microenvironment. PD-1/PD-L1 PET imaging enables to study of these interactions in the tumor microenvironment in a clinical setting. These noninvasive, sensitive and quantitative tools may play an important role in optimizing ICI efficacy.
Keywords: Cancer; Checkpoint inhibitors; Immunotherapy; Molecular imaging; PD-1; PD-L1; immunoPET.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.